Among an inner London UK cohort of 147 adolescents transitioning from paediatric into adult care between 2007 and 2015, a new diagnosis of lymphoma was made in five patients; incidence rate U 0.425/100 person-years (95% confidence interval U 0.424-0.426). Previously described risk factors, including low nadir CD4 R cell count and ongoing HIV-1 viraemia, appeared to be important. These data suggest that careful surveillance and a low threshold for investigating relevant symptoms continue to be essential for such patients.
HIV-1-infected (HIVþ) children and adolescents are at significant risk of non-Hodgkin lymphoma (NHL), most typically diffuse large B-cell (DLBC), high-grade plasmablastic, or Burkitt variants [1, 2] . The risk of developing lymphoma in HIV-infected individuals appears directly related to nadir CD4 þ cell count [3] [4] [5] and to ongoing HIV viraemia. Consistent virological suppression with antiretroviral therapy (ART) is, by contrast, highly protective [5, 6] . During the pre-and early-ART era, profound immunosuppression and detectable viraemia were common occurrences in HIVþ children, and antiretroviral options were limited by significant toxicities, unpalatable formulations and poor virological durability [7, 8] . Early ART regimens were frequently unlicensed, and therefore underpinned by low-quality clinical evidence, in paediatric populations. As a result, inadvertent under-dosing was observed in up to 62% of children in the UK and Ireland between 1997 and 2005 [9] . Virological failure and subsequent accumulation of resistance-associated mutations are therefore common in this population at the point of transition to adult services [10] . Thus, despite the advantages of modern ART regimens and multidisciplinary care in resource-rich countries, many adolescents with vertically acquired HIV will bear the burden of chronic, sub-optimal virological control in childhood alongside the significant challenges of maintaining consistent treatment concordance (and virological suppression) during adolescence [11] .
We conducted a retrospective review of all new lymphoma diagnoses in a cohort of adolescents transitioning from paediatric to an adult HIV service between January 2007 and January 2015. Our service, based at Mortimer Market Centre in Central London, provides free HIV-care for around 4500 patients aged over 15 years from all areas of the UK including a dedicated adolescent clinic to support transition between paediatric and adult HIV services.
Over the 8-year period, 147 individuals transitioned their HIV care to our service from paediatric services. Among these, we identified five new cases of lymphoma. The total observation time was 1176 person-years. Three patients were male. The median age at HIV-1 diagnosis was 6 years (range 0-17 years) and 19 years (range 18-23) at lymphoma diagnosis, respectively. Median (range) CD4 þ cell counts at lymphoma diagnosis and pre-ART nadir were 340 (180-550) and 157 (90-220) cells/ml, respectively. All five patients were known to have a history of intermittent or complete nonadherence in the 5 years prior to transitioning care, although three were known to have an undetectable HIV-1 viral load at lymphoma diagnosis. Full, historical HIV-1 viral load data were available for four patients (Fig. 1 ). The mean time from initial engagement with HIV services to lymphoma diagnosis was 114 months (range 30-199). Mean estimated cumulative exposure to detectable HIV-1 viraemia (obtained via historical viral load data, clinic attendance notes and electronic prescriptions for ART) was 170.5 months (range 118-234). Dual and triple-class ART resistance was present in one and two patients, respectively; all patients had durable therapeutic options available to them at lymphoma diagnosis. Four patients had DLBC; the fifth had marginal zone lymphoma which transformed during chemotherapy to a high-grade DLBC. All five patients had disseminated disease (Ann Arbor stage III or IV) at initial presentation: B symptoms were present in four. Immunohistochemistry showed four were positive for Epstein-Barr virus (EBV)encoded small RNAs (EBERs). Quantitative assessment of blood/tumour EBV load is not part of routine clinical assessment at diagnosis of HIV-associated lymphoma in the UK [12] . Likewise, markers of immune activation, such as tumour necrosis factor-a, b-microglobulin, and interleukin-10, are not assayed routinely in HIV-infected patients in our treatment centre.
The lymphoma incidence-rate for these five patients over the eight-year period is 0.425/100 person-years [95% confidence interval (CI) ¼ 0.424-0.426]. This figure is similar to rates previously reported in HIV-infected children and infants during the pre-ART era (incidence rate ¼ 0.386/100 person-years, 95% CI ¼ 0.386-0.387: incidence-rate ratio ¼ 1.10; 95% CI ¼ 0.98-1.24, P ¼ 0.1) [1] . Moreover, the incidence rate of NHL seen in this cohort significantly exceeds the average rate observed between 2008 and 2010 among [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] year olds in the UK general population (incidence rate ¼ 6.4/ 100 000 person-years, 95% CI ¼ 4.93-8.17: incidencerate ratio ¼ 25.9; 95% CI ¼ 8.31-61.7, P < 0.0001) [13] .
It is established that the risk of developing HIV-associated lymphoma at any given time-point directly relates to the magnitude of immunosuppression. More specifically, data from several cohort studies suggest that current (rather than nadir) CD4 þ cell count and HIV-1 viral load are the most significant parameters in determining lymphomarisk in multivariate analysis [6, 14, 15] . It is also suggested that cumulative exposure to detectable HIV-1 viraemia increases lymphoma-risk in a dose-dependent fashion [16] . These observations are borne out in the wider epidemiology, such that the observed incidence of HIVassociated NHL has fallen by up to 90% during the ART era [15, 17] . Nevertheless, the incidence of NHL observed in our cohort is in stark excess of that observed in both the age-matched UK general population and in a cohort of HIV-infected adults with undetectable viraemia on ART -a reasonable model, we suggest, for the wider UK population in specialist HIV care [18] . Likewise, despite the universal availability of effective ART, the observed rate of lymphoma in our cohort was comparable to that seen in UK children with AIDS in the pre-ART era.
All of the lymphoma cases observed in our cohort occurred in adolescents with a prolonged history of poor ART concordance and detectable HIV-1 viraemia during childhood and early adolescence. Although the small sample size limits firm conclusions, we hypothesise that this represents a perfect scenario for the development of lymphoma. Uncontrolled HIV-1 infection engenders a significant pro-inflammatory state, with high levels of immune activation occurring synchronously with immunosuppression [19, 20] . B-lymphocyte hyperstimulation, as indicated by polyclonal hypergammaglobulinaemia, is a key feature [21] . This phenomenon is amplified in the HIV-infected child as the nascent immune system fails to co-ordinate an efficient response to HIV-1 with higher viraemic set points and a faster progression to AIDS compared with those infected during later life [22] [23] [24] . Therefore, HIV-infected children bear a particularly heavy burden of immunosuppression, resulting in impaired surveillance and cytotoxic control of malignant cells and oncogenic viruses.
EBV is the most common oncogenic virus involved in the pathogenesis of HIV-associated lymphoma, with plasma EBV viral load correlating directly with risk [25] . Higher plasmaEBVDNAloadshavebeenobservedinchildrenwith uncontrolled HIV-1 infection compared with age-matched counterparts taking effective ART [26, 27] . Moreover, coinfection with EBV types 1 and 2 appears more common in children with uncontrolled HIV-1, which may further increase the risk of lymphomagenesis [28] . We therefore postulate that the potent theoretical interactions between uncontrolled HIV-1 infection, oncogenic viruses and an immature immune system serve to greatly increase lymphoma-risk in HIV-infected adolescents with vertically acquired infection over that seen in those infected via other routes. However, we acknowledge that the lack of supplementary data concerning quantitative EBVexposure and immune activation in our patients may limit firm conclusions in this regard.
With increased survival of children with vertically acquired HIV infection, the numbers of adolescents transitioning from paediatric to adult HIV services in the UK has significantly increased in recent years, and although numerically a small group, these patients require considerable specialist care. This is important not only to support ART concordance at a time of immense psychosocial challenge, but also to monitor for nascent complications associated with past or present immunosuppression. Our findings suggest that clinicians caring for adolescents with vertically acquired HIV infection should maintain a high level of vigilance for symptoms suggestive of lymphoma and should have a low threshold for diagnostic evaluation, even in the presence of undetectable viraemia on ART.
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